EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent

Raju Subramanian iD, Jennifer Tang, Jim Zheng, Bing Lu, Kelly Wang, Stephen R Yant, George J Stepan, Andrew Mulato, Helen Yu, Scott Schroeder, Naveed Shaik, Renu Singh und 8 weitere

Molecular Pharmaceutics · 04.12.2023 · 20 (12) · 6213-6225

DOI: 10.1021/acs.molpharmaceut.3c00626 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 02.11.2023. Verfasst von Raju Subramanian und 19 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States. Hauptthemen laut MEDLINE: HIV-1, Anti-HIV Agents. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lenacapavir (LEN) is a picomolar first-in-class capsid inhibitor of human immunodeficiency virus type 1 (HIV-1) with a multistage mechanism of action and no known cross resistance to other existing antiretroviral (ARV) drug classes. LEN exhibits a low aqueous solubility and exceptionally low systemic clearance following intravenous (IV) administration in nonclinical species and humans. LEN formulated in an aqueous suspension or a PEG/water solution formulation showed sustained plasma exposure levels with no unintended rapid drug release following subcutaneous (SC) administration to rats and dogs. A high total fraction dose release was observed with both formulations. The long-acting pharmacokinetics (PK) were recapitulated in humans following SC administration of both formulations. The SC PK profiles displayed two-phase absorption kinetics in both animals and humans with an initial fast-release absorption phase, followed by a slow-release absorption phase. Noncompartmental and compartmental analyses informed the LEN systemic input rate from the SC depot and exit rate from the body. Modeling-enabled deconvolution of the input rates from two processes: absorption of the soluble fraction (minor) from a direct fast-release process leading to the early PK phase and absorption of the precipitated fraction (major) from an indirect slow-release process leading to the later PK phase. LEN SC PK showed flip-flop kinetics due to the input rate being substantially slower than the systemic exit rate. LEN input rates via the slow-release process in humans were slower than those in both rats and dogs. Overall, the combination of high potency, exceptional stability, and optimal release rate from the injection depot make LEN well suited for a parenteral long-acting formulation that can be administered once up to every 6 months in humans for the prevention and treatment of HIV-1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Anti-HIV AgentsHumansRatsAnimalsDogsAnti-Retroviral AgentsCapsidCapsid Proteins

Stichwörter der Autor:innen

HIV-1 capsid inhibitorPK modelingcombination antiretroviral therapyhuman PKlong-acting injectablenonclinical pharmacokinetics

Substanzen

Anti-Retroviral AgentsAnti-HIV AgentsCapsid Proteins

Autor:innen und Institutionen

  • Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States.

ORCID-Profile: Raju Subramanian

Förderung

  • Gilead Sciences

Zitieren

APA

Subramanian, R., Tang, J., Zheng, J., Lu, B., Wang, K., Yant, S. R., Stepan, G. J., Mulato, A., Yu, H., Schroeder, S., Shaik, N., Singh, R., Wolckenhauer, S., Chester, A., Tse, W. C., Chiu, A., Rhee, M., Cihlar, T., Rowe, W., & Smith, B. J. (2023). Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent. Molecular Pharmaceutics, 20(12), 6213-6225. https://doi.org/10.1021/acs.molpharmaceut.3c00626

Vancouver

Subramanian R, Tang J, Zheng J, Lu B, Wang K, Yant SR, et al. Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent. Molecular Pharmaceutics. 2023;20(12):6213-6225. doi:10.1021/acs.molpharmaceut.3c00626

BibTeX
@article{Subramanian2023,
  author = {Subramanian, Raju and Tang, Jennifer and Zheng, Jim and Lu, Bing and Wang, Kelly and Yant, Stephen R and Stepan, George J and Mulato, Andrew and Yu, Helen and Schroeder, Scott and Shaik, Naveed and Singh, Renu and Wolckenhauer, Scott and Chester, Anne and Tse, Winston C and Chiu, Anna and Rhee, Martin and Cihlar, Tomas and Rowe, William and Smith, Bill J},
  title = {Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  volume = {20},
  number = {12},
  pages = {6213--6225},
  doi = {10.1021/acs.molpharmaceut.3c00626}
}
Kostenlos starten →